RESEARCH-USE BIOSIMILAR ANTIBODY

Favezelimab

Monoclonal antibody · IgG4

LAG3IgG4RUO

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

TARGETLAG3
YMonoclonal antibody
CATALOGSC-BS-544
CATALOG NUMBERSC-BS-544
MOLECULAR WEIGHTApprox. 145.98 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Favezelimab is a recombinant research-use antibody directed against LAG3.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Favezelimab | StellaCyte